Safety-Related Gocovri Labeling Changes Approved
FDA has approved safety-related labeling changes for Adamas Pharmaceuticals Parkinson’s drug Gocovri (amantadine HCl). The changes involve adding a postmarketing experience subsection to the Adverse Reactions section of the label and revising the Patient Counseling Information/Patient Information/Medication Guide.